A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature, vol.390, issue.6656, pp.175-179, 1997. ,
DOI : 10.1038/36593
A nucleosomal function for I??B kinase-?? in NF-??B-dependent gene expression, Nature, vol.423, issue.6940, pp.659-663, 2003. ,
DOI : 10.1038/nature01648
A murine model of experimental metastasis to bone and bone marrow, Cancer Res, vol.48, pp.6876-6881, 1988. ,
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes, The Prostate, vol.32, issue.1, pp.92-104, 2008. ,
DOI : 10.1002/pros.20678
Bone versus immune system, Nature, vol.408, pp.535-536, 2000. ,
Platelet and osteoclast beta3 integrins are critical for bone metastasis, Proc. Natl. Acad. Sci. USA, pp.14205-14210, 2003. ,
Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma, Clin. Cancer Res, vol.11, pp.162-165, 2005. ,
Osteoprotegerin and rank ligand expression in prostate cancer, Urology, vol.57, issue.4, pp.611-616, 2001. ,
DOI : 10.1016/S0090-4295(00)01122-5
Expression and function of TNF-family proteins and receptors in human osteoblasts???, Bone, vol.33, issue.5, pp.760-770, 2003. ,
DOI : 10.1016/j.bone.2003.07.006
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis, Clinical & Experimental Metastasis, vol.23, issue.Supp 1, pp.119-129, 2008. ,
DOI : 10.1007/s10585-007-9127-1
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation, Cancer, vol.18, issue.2, pp.289-298, 2006. ,
DOI : 10.1002/cncr.21978
Skeletal complications of malignancy, Cancer, vol.12, issue.S8, pp.1588-1594, 1997. ,
DOI : 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G
Osteoprotegerin in Prostate Cancer Bone Metastasis, Cancer Research, vol.65, issue.5, pp.1710-1718, 2005. ,
DOI : 10.1158/0008-5472.CAN-04-2033
The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development, Cell, vol.103, issue.1, pp.41-50, 2000. ,
DOI : 10.1016/S0092-8674(00)00103-3
Osteolysis and cancer, Journal of Clinical Investigation, vol.107, issue.10, pp.1219-1220, 2001. ,
DOI : 10.1172/JCI13073
Molecular mechanisms of osteolytic bone metastases, Cancer, vol.283, issue.S12, pp.2892-2898, 2000. ,
DOI : 10.1002/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO;2-Y
Overview of Sarcomas in the Adolescent and Young Adult Population, Journal of Pediatric Hematology/Oncology, vol.27, issue.4, pp.215-218, 2005. ,
DOI : 10.1097/01.mph.0000161762.53175.e4
Gene Expression of Osteoprotegerin Ligand, Osteoprotegerin, and Receptor Activator of NF-??B in Giant Cell Tumor of Bone, The American Journal of Pathology, vol.156, issue.3, pp.761-767, 2000. ,
DOI : 10.1016/S0002-9440(10)64942-5
Cancer Statistics, 2007, CA: A Cancer Journal for Clinicians, vol.57, issue.1, pp.43-66, 2007. ,
DOI : 10.3322/canjclin.57.1.43
Regulation of cancer cell migration and bone metastasis by RANKL, Nature, vol.17, issue.7084, pp.692-696, 2006. ,
DOI : 10.1038/nature04524
Mechanisms of osteolytic bone metastases in breast carcinoma, Cancer, vol.134, issue.S3, pp.834-839, 2003. ,
DOI : 10.1002/cncr.11132
Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma, Blood, vol.73, pp.2145-2148, 1989. ,
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, vol.397, pp.315-323, 1999. ,
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation, Cell, vol.93, issue.2, pp.165-176, 1998. ,
DOI : 10.1016/S0092-8674(00)81569-X
Therapeutic Relevance of Osteoprotegerin Gene Therapy in Osteosarcoma: Blockade of the Vicious Cycle between Tumor Cell Proliferation and Bone Resorption, Cancer Research, vol.67, issue.15, pp.7308-7318, 2007. ,
DOI : 10.1158/0008-5472.CAN-06-4130
Cancer statistics, 1999, Cancer statistics, pp.8-31, 1999. ,
DOI : 10.3322/canjclin.49.1.8
Nuclear Localization in the Biology of the CD40 Receptor in Normal and Neoplastic Human B Lymphocytes, Journal of Biological Chemistry, vol.281, issue.27, pp.18878-18887, 2006. ,
DOI : 10.1074/jbc.M513315200
Nuclear localization of EGF receptor and its potential new role as a transcription factor, Nature Cell Biology, vol.3, issue.9, pp.802-808, 2001. ,
DOI : 10.1038/ncb0901-802
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate, Journal of Clinical Oncology, vol.23, issue.9, 2004. ,
DOI : 10.1200/JCO.2005.06.031
The N-terminal domains target TNF receptorassociated factor-2 to the nucleus and display transcriptional regulatory activity, J. Immunol, vol.161, pp.319-324, 1998. ,
Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells, International Immunopharmacology, vol.2, issue.1, pp.25-38, 2002. ,
DOI : 10.1016/S1567-5769(01)00134-5
Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells, Oncol. Rep, vol.18, pp.1365-1371, 2007. ,
URL : https://hal.archives-ouvertes.fr/inserm-00667508
Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B, The Journal of Pathology, vol.186, issue.5, pp.555-562, 2007. ,
DOI : 10.1002/path.2140
DU145 human prostate cancer cells express functional receptor activator of NF??B: New insights in the prostate cancer bone metastasis process, Bone, vol.40, issue.4, pp.981-990, 2007. ,
DOI : 10.1016/j.bone.2006.11.006
Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor?????B ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton, Acta Oncologica, vol.23, issue.2, pp.221-229, 2007. ,
DOI : 10.1158/1078-0432.CCR-0565-3
Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities, Nature Reviews Cancer, vol.2, issue.8, pp.584-593, 2002. ,
DOI : 10.1038/nrc867
RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis, Biochemical and Biophysical Research Communications, vol.253, issue.2, pp.395-400, 1998. ,
DOI : 10.1006/bbrc.1998.9788
Alteration of Integrins by Heparin-Binding EGF Like Growth Factor in Human Breast Cancer Cells, Oncology, vol.53, issue.5, pp.374-381, 1996. ,
DOI : 10.1159/000227591
The distrubution of secondary growths in cancer of the breast, Lancet, vol.1, pp.571-572, 1889. ,
Integrative nuclear FGFR1 signaling (INFS) pathway mediates activation of the tyrosine hydroxylase gene by angiotensin II, depolarization and protein kinase C, Journal of Neurochemistry, vol.268, issue.3, pp.506-524, 2002. ,
DOI : 10.1046/j.1471-4159.2002.00833.x
Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts, Journal of Cellular Biochemistry, vol.95, issue.4, pp.650-659, 2003. ,
DOI : 10.1002/jcb.10436
Mechanisms of Bone Metastasis, New England Journal of Medicine, vol.350, issue.16, pp.1655-1664, 2004. ,
DOI : 10.1056/NEJMra030831
Direct osteolysis induced by metastatic murine melanoma cells: Role of matrix metalloproteinases, European Journal of Cancer, vol.33, issue.6, pp.918-925, 1997. ,
DOI : 10.1016/S0959-8049(97)00513-3
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density, Cell, vol.89, issue.2, pp.309-319, 1997. ,
DOI : 10.1016/S0092-8674(00)80209-3
Bone tumours in European children and adolescents, 1978???1997. Report from the Automated Childhood Cancer Information System project, European Journal of Cancer, vol.42, issue.13, pp.2124-2135, 2006. ,
DOI : 10.1016/j.ejca.2006.05.015
OPG/membranous???RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation, Bone, vol.39, issue.4, pp.706-715, 2006. ,
DOI : 10.1016/j.bone.2006.03.016
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling, Cytokine & Growth Factor Reviews, vol.15, issue.6, pp.457-475, 2004. ,
DOI : 10.1016/j.cytogfr.2004.06.004
The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone, Journal of Orthopaedic Research, vol.63, issue.6, pp.1475-1483, 2005. ,
DOI : 10.1016/j.orthres.2005.05.004.1100230634
RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells, International Journal of Oncology, vol.28, pp.261-269, 2006. ,
DOI : 10.3892/ijo.28.1.261
URL : https://hal.archives-ouvertes.fr/inserm-00667510
TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell???specific Survival Factor, The Journal of Experimental Medicine, vol.372, issue.12, pp.2075-2080, 1997. ,
DOI : 10.1084/jem.183.1.7
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proc. Natl. Acad. Sci. USA 95, pp.3597-3602, 1998. ,
DOI : 10.1073/pnas.95.7.3597
Osteoprotegerin inhibits prostate cancer???induced osteoclastogenesis and prevents prostate tumor growth in the bone, Journal of Clinical Investigation, vol.107, issue.10, pp.1235-1244, 2001. ,
DOI : 10.1172/JCI11685
Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone, Cancer Res, vol.63, pp.7883-7890, 2003. ,